Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials

Lenoci, Deborah;Carenzo, Andrea;Cavalieri, Stefano;Pistore, Federico;De Cecco, Loris;et.al.
(2022) Oral Oncology — Vol. 126, p. 105756 [1-4] (2022)

Files

1-s20-S1368837522000458-main.pdf
  • Open Access
  • Adobe PDF
  • 1022.69 KB
Download

Details

Authors
Show more
Abstract
(en) INTRODUCTION : In head and neck squamous cell carcinoma (HNSCC) patients, the use of drugs acting against the epidermal growth factor receptor (EGFR) [1], has shown to be beneficial in curative and palliative settings. Treating HNSCC patients through biomarkers able to predict response and linked to the biological effect of treatments should be advisable, but no biomarkers other than PD-L1 expression have entered into clinical practice so far. This purpose could be achieved through window-of-opportunity (WOO) trials [2], in which non-pretreated patients receive neo-adjuvant drugs before standard-of-care therapy. The aim of these studies is the evaluation of the biological activity, which is variously defined according to the drug under study. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lenoci, D., Carenzo, A., Cavalieri, S., Pistore, F., Serafini, M. S., Bossi, P., Schmitz, S., Machiels, J.-P., Licitra, L. F., & De Cecco, L. (2022). Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. Oral Oncology, 126, 105756 [1-4]. https://doi.org/10.1016/j.oraloncology.2022.105756 (Original work published 2022)